Hepatitis C occurs due to infection with HCV, the virus responsible for causing many other liver diseases (cirrhosis, liver cancer). People with hepatitis C need immediate medical treatment in order to prevent the development of complications. Statistics reveal that hepatitis C affects around 150.000 people in the United States each year, and many people with the acute form of the disease can in time develop chronic hepatitis C. Furthermore, many patients with inappropriately treated chronic hepatitis C can in time develop cirrhosis and even end-stage liver disease. Although hepatitis C can be transmitted solely through direct contact with infected blood or body secretions, an overwhelmingly large number of people worldwide are diagnosed with the disease each year.
In the absence of hepatitis C treatment, people with this form of liver disease can experience a rapid aggravation of their overall health condition. Considering the fact that the liver is a vital organ, people who suffer from hepatitis C can develop many other diseases due to abnormal activity of the liver. Hepatitis C treatments available today can overcome the disease and prevent the occurrence of complications. While people diagnosed with acute forms of the disease respond very well to short-term hepatitis C treatments, people with chronic forms of the disease require long-term, ongoing specific medical treatment in order to recover completely.
There are many hepatitis C treatments available today. However, the most effective form of hepatitis C treatment involves the administration of alpha interferon. Interferon is a protein produced in small amounts by the human body and it was initially used in the treatment for leukemia. These days, alpha interferon is a product used in the majority of hepatitis C treatments and it is considered to be the best option in curing the disease. Hepatitis C treatments with alpha interferon are recommended for patients with serious forms of the disease, as well as for patients with milder liver affections.
Patients are selected for hepatitis C treatment with interferon if they present recidivating liver dysfunctions. Hepatitis C doesn’t always generate conclusive sets of symptoms and the best means of diagnosing the disease are blood analyses and sometimes liver biopsy. About 50 percent of the patients that receive hepatitis C treatment with interferon experience a considerable amelioration of their symptoms and they eventually recover completely from the disease.
However, other patients experience a regression of their disease only during the hepatitis C treatment with interferon, their symptoms reoccurring rapidly after the treatment is interrupted. Statistics indicate that about 50 percent of patients that receive hepatitis C treatment with interferon experience a relapse of their disease within a few months after the treatment is completed. However, this is the case of patients with chronic forms of disease. Most patients who receive hepatitis C treatment with interferon in the acute form of the disease don’t experience a recurrence of hepatitis C.
Hepatitis C treatment with interferon is mostly effective in the initial stage of disease and in treating acute hepatitis C. For people who suffer from chronic hepatitis C or complicated forms of the disease, combined medical treatments are required. Nowadays, hepatitis C treatments involve both the use of interferon and anti-viral medications, thus decreasing the chances of relapse in the case of patients with chronic forms of the disease.